The incidence of prostate cancer was significantly higher in MSH2 carriers than in non-carrier controls and in MSH6 carriers than in non-carrier controls, adding further weight to the increased risk associated with these genes specifically; however, no specific pathogenic variant or gene region was associated with the cancer cases. Here, MSH2 is linked to prostate carcinoma.